Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2174 - Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight


09 Oct 2016


Poster display


Pascaline Boudou Rouquette


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


P. Boudou Rouquette1, A. Jouinot1, O. Huillard1, J. Arrondeau1, C. Tlemsani1, V. Heidelberg1, J. Chapron2, N. Kramkimel3, D. Damotte4, F. Batteux5, L. Dehghani6, B. Terrier7, L. Groussin8, N. Dupin3, B. Blanchet9, M. Alifano10, K. Leroy11, M. Revel12, J. Alexandre1, F. Goldwasser1

Author affiliations

  • 1 Medical Oncology, Certim, Hôpital Cochin, 75014 - Paris/FR
  • 2 Pneumo-oncology, Hôpital Cochin, 75014 - Paris/FR
  • 3 Onco-dermatology, Hôpital Cochin, 75014 - Paris/FR
  • 4 Pathology, Hôpital Cochin, 75014 - Paris/FR
  • 5 Immunology, Hôpital Cochin, 75014 - Paris/FR
  • 6 Diabetology, Hôpital Cochin, 75014 - Paris/FR
  • 7 Internal Medicine, Hôpital Cochin, 75014 - Paris/FR
  • 8 Endocrinology, Hôpital Cochin, 75014 - Paris/FR
  • 9 Functional Unit Of Pharmacokinetics And Pharmacochemistry, Hôpital Cochin, 75014 - Paris/FR
  • 10 Thoracic Surgery, Hôpital Cochin, 75014 - Paris/FR
  • 11 Biology, Hôpital Cochin, Paris/FR
  • 12 Radiology, Hôpital Cochin, Paris/FR


Abstract 2174


PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse events (irAEs). Body composition has been proven to influence the pharmacokinetics of many anti-neoplastic drugs. We evaluated the effect of decreased muscle mass (sarcopenia) on PD-1 inhibitors toxicity.


Pre-therapeutic biological and clinical assessments were prospectively performed for patients (pts) treated with anti-PD1. Muscle mass was estimated using Creatinine/Cystatine C (Cr/CysC) clearance ratio (Kim SW, 2016). Univariate and multivariate analysis tested the association between anti-PD1 induced severe toxicity and age, sex, Performans Status (PS), (Cr/CysC) clearance ratio, body mass index (BMI), lymphocytes, C-Reactive Protein (CRP) and albuminemia. The severity of AEs was graded according to the NCI CTC for AE V4.


From July 2015 to April 2016, 74 pts, median age 65 years (41-84), 58.1% men, received at least one infusion of nivolumab (85%) or pembrolizumab (15%), for lung cancer (n = 44), melanoma (n = 13), renal carcinoma (n = 9) and others (n = 8). A total of 418 cycles (median per pt: 4, range 1-20) were analyzed. Median Cr/CysC clearance ratio was 1.17. Twenty pts (27%) had both Cr/CysC clearance ratio >1.17, reflecting low lean body mass and a BMI > 25 kg.m−2. Fifteen pts (20.2%) developed grade 3-5 AEs, some rare, such as insipid diabetes with hypophysitis (n = 1) after 1st cycle (C1), pulmonary arterial hypertension (n = 3, C1, C1, C5), polymyositis (n = 2, C2, C2) and thrombocytopenia (n = 1, C6). In univariate analysis, gr 3-5 AE was associated with Cr/CysC clearance ratio >1.17 (p = 0.006), high CRP (p = 0.036) and the combination of Cr/Cyst clearance ratio >1.17 with BMI > 25 kg/m2 (p= 0.024). In multivariate analysis, Cr/CysC clearance ratio >1.17 (p = 0.03) and the combination of Cr/CysC clearance ratio >1.17 with BMI >25 kg/m2 (p = 0.014) remained significant.


The Creatinine/Cystatine C clearance ratio associated with BMI helps to identify sarcopenic overweight pts who are at high risk of severe PD-1 inhibitors induced toxicity. To date, it is unknown if the development of irAEs is an inherent component of checkpoint blockade with anti–PD-1 or if modifying the dosage can decrease the rates of these events.

Clinical trial identification

Legal entity responsible for the study

Pascaline Boudou-Rouquette




D. Damotte: research contract (MSD) All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings